Valion Bio, Inc. (VBIO)
1.17
-0.06
(-4.88%)
USD |
NASDAQ |
Oct 16, 16:00
1.14
-0.03
(-2.56%)
After-Hours: 20:00
Valion Bio Enterprise Value : 23.13M for Oct. 16, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 16, 2026 | 23.13M |
| October 15, 2026 | 23.14M |
| October 14, 2026 | 23.18M |
| October 13, 2026 | 23.20M |
| October 12, 2026 | 23.22M |
| October 09, 2026 | 23.30M |
| October 08, 2026 | 23.31M |
| October 07, 2026 | 23.30M |
| October 06, 2026 | 23.34M |
| October 05, 2026 | 23.35M |
| October 02, 2026 | 23.37M |
| October 01, 2026 | 23.36M |
| September 30, 2026 | 23.41M |
| September 29, 2026 | 23.41M |
| September 28, 2026 | 23.39M |
| September 25, 2026 | 23.44M |
| September 24, 2026 | 23.52M |
| September 23, 2026 | 23.39M |
| September 22, 2026 | 23.35M |
| September 21, 2026 | 23.34M |
| September 18, 2026 | 23.29M |
| September 17, 2026 | 23.31M |
| September 16, 2026 | 23.29M |
| September 15, 2026 | 23.29M |
| September 14, 2026 | 23.29M |
| Date | Value |
|---|---|
| September 11, 2026 | 23.32M |
| September 10, 2026 | 23.31M |
| September 09, 2026 | 23.34M |
| September 08, 2026 | 23.36M |
| September 04, 2026 | 23.40M |
| September 03, 2026 | 23.41M |
| September 02, 2026 | 23.46M |
| September 01, 2026 | 23.45M |
| August 31, 2026 | 23.53M |
| August 28, 2026 | 23.44M |
| August 27, 2026 | 23.45M |
| August 26, 2026 | 23.59M |
| August 25, 2026 | 23.60M |
| August 24, 2026 | 23.63M |
| August 21, 2026 | 23.45M |
| August 20, 2026 | 23.45M |
| August 19, 2026 | 23.50M |
| August 18, 2026 | 23.61M |
| August 17, 2026 | 23.70M |
| August 14, 2026 | 23.73M |
| August 13, 2026 | 23.65M |
| August 12, 2026 | 23.88M |
| August 11, 2026 | 24.23M |
| August 10, 2026 | 24.14M |
| August 07, 2026 | 24.13M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Outlook Therapeutics, Inc. | 98.53M |
| Agenus, Inc. | 522.06M |
| Amgen, Inc. | 277.12B |
| Anika Therapeutics, Inc. | 254.23M |
| BioCryst Pharmaceuticals, Inc. | 2.472B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -7.057M |
| Total Expenses (Quarterly) | 7.057M |
| EPS Diluted (Quarterly) | -52.54 |
| Earnings Yield | -17.97K% |
| Normalized Earnings Yield | -18005.50 |